539,190 Shares in Guardant Health, Inc. $GH Bought by Westfield Capital Management Co. LP

Westfield Capital Management Co. LP bought a new position in Guardant Health, Inc. (NASDAQ:GH) during the fourth quarter, according to its most recent disclosure with the SEC. The firm bought 539,190 shares of the company’s stock, valued at approximately $55,073,000. Westfield Capital Management Co. LP owned 0.43% of Guardant Health as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of GH. V Square Quantitative Management LLC bought a new position in Guardant Health in the 4th quarter worth $27,000. Chesapeake Asset Management LLC bought a new stake in Guardant Health during the fourth quarter valued at about $28,000. Thurston Springer Miller Herd & Titak Inc. bought a new stake in Guardant Health during the fourth quarter valued at about $31,000. Elyxium Wealth LLC bought a new stake in Guardant Health during the fourth quarter valued at about $35,000. Finally, First Pacific Financial bought a new stake in Guardant Health during the fourth quarter valued at about $43,000. 92.60% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. Canaccord Genuity Group raised their price target on Guardant Health from $125.00 to $135.00 and gave the company a “buy” rating in a report on Friday, February 20th. Piper Sandler set a $127.00 price target on Guardant Health in a report on Thursday, May 21st. Wells Fargo & Company raised their price objective on Guardant Health from $120.00 to $125.00 and gave the company an “overweight” rating in a research report on Friday, February 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Guardant Health in a research report on Tuesday, April 21st. Finally, TD Cowen restated a “buy” rating on shares of Guardant Health in a research report on Thursday, May 21st. Two research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Guardant Health has an average rating of “Buy” and a consensus target price of $137.80.

Insider Transactions at Guardant Health

In related news, insider John G. Saia sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 27th. The stock was sold at an average price of $125.08, for a total value of $1,250,800.00. Following the completion of the sale, the insider owned 35,950 shares in the company, valued at approximately $4,496,626. The trade was a 21.76% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Meghan V. Joyce sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 3rd. The shares were sold at an average price of $126.98, for a total value of $1,269,800.00. Following the completion of the sale, the director owned 11,183 shares of the company’s stock, valued at $1,420,017.34. The trade was a 47.21% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 350,238 shares of company stock valued at $38,538,372 in the last ninety days. Corporate insiders own 5.60% of the company’s stock.

Guardant Health Price Performance

Shares of NASDAQ:GH opened at $125.61 on Friday. Guardant Health, Inc. has a 1 year low of $40.35 and a 1 year high of $134.28. The business has a 50 day simple moving average of $99.39 and a two-hundred day simple moving average of $101.08. The firm has a market capitalization of $16.66 billion, a PE ratio of -37.05 and a beta of 1.61.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.